BTIG Maintains Buy on Cullinan Oncology, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman has maintained a Buy rating on Cullinan Oncology (NASDAQ:CGEM) and increased the price target from $20 to $30.
April 17, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Kaveri Pohlman reaffirmed a Buy rating on Cullinan Oncology and raised the price target to $30 from $20.
The increase in price target by a reputable analyst like Kaveri Pohlman from BTIG is a strong positive signal for Cullinan Oncology. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100